ois.net #OISAAO

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGY

INTERWEST PARTNERSGILBERT H. KLIMAN, MD

MODERATED BY:MODERATED BY:

ois.net #OISAAO

VERILY LIFE SCIENCES

DIMITRIAZAR, MD

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGYMARKET OVERVIEW

3

ois.net #OISAAO

GENENTECH

JILLHOPKINS, MD

VERILY LIFE SCIENCES

DIMITRIAZAR, MD

CARL ZEISS MEDITEC

ANGELORAGO

PHILIPS

DALEWIGGINS

INTERWEST PARTNERS

GILBERT H.KLIMAN, MD

MODERATED BY:

SANTEN

ELLIECHABI, MD

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGYSTRATEGIC PANEL

4

ois.net #OISAAO

5

Dale WigginsVP & GM HealthSuite digital platform

AI in Healthcare

Applying AI to enable integrated personalized care anytime, anywhere and to support optimized care operations

Context Context

Personalized care

Adaptive IntelligenceAdaptive: dynamically change in response to you

Embedded: connected devices integrated into the environment

Context-aware: devices recognize you and your context

Natural: converse in a natural way

Precise: multi-modality perspective to get precise measurements and insights

Personalized: configured to your needs

Predictive: anticipate your condition & needs

Pro-active: preventative, early intervention Digital Twin

Protecting the World’s Vision

Copyright© 2018 Santen Inc. All rights reserved.

OIS@AAO 2018Ellie Chabi, MD | Therapeutic Area Head, Glaucoma & Neuroprotection

October 25, 2018

A STRONG FOUNDATION IN OPHTHALMOLOGY

Countries where specialty ophthalmic products are sold

Established in Osaka, Japan, the first ophthalmology company of its kind

First ophthalmic product launched

1890

60+

$2.25

1899

Employees worldwide 4,000

Billion in revenue in FY2017

SANTEN COMMITMENTPreserving vision with innovative ophthalmic products

Exclusive to ophthalmology with a

long-term view

Accelerate innovation through strategic

partnerships

Develop therapeutic solutions focused on

unmet needs

1. THERAPEUTIC SOLUTIONS, INCLUDING: • Glaucoma & Neuroprotection• Retinal Diseases• Dry Eye and External Diseases

Partnering Opportunities

2. MACHINE LEARNING / AI3. BIOMARKERS AND DIAGNOSTIC TOOLS4. DRUG DELIVERY

ois.net #OISAAO

13

ois.net #OISAAO

GENENTECH

JILLHOPKINS, MD

VERILY LIFE SCIENCES

DIMITRIAZAR, MD

CARL ZEISS MEDITEC

ANGELORAGO

PHILIPS

DALEWIGGINS

INTERWEST PARTNERS

GILBERT H.KLIMAN, MD

MODERATED BY:

SANTEN

ELLIECHABI, MD

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGYSTRATEGIC PANEL

14

ois.net #OISAAO

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGYPRESENTING COMPANIES

15

ois.net #OISAAO

Potential Questions for Companies• What are the data inputs and what algorithms drive your technology?• Is the process fixed or is there “machine learning” involved?• To what degree are humans required for interpretation/operation?• What FDA approval is required and who pays for the technology?• What interventions can be driven directly or indirectly by the technology?

16

ois.net #OISAAO

RISE OF AI AND ANALYTICS IN OPHTHALMOLOGY

Thank you!

17